RestructuringApr 9, 2026, 09:31 AM
Quince Therapeutics to Implement 1-for-10 Reverse Stock Split Effective April 10, 2026
AI Summary
Quince Therapeutics, Inc. (QNCX) announced the implementation of a 1-for-10 reverse stock split, following stockholder approval on June 4, 2025. The company's board of directors approved the action, and the Certificate of Amendment was filed on April 9, 2026, becoming effective at 11:59 pm Eastern Time on April 10, 2026. This move is typically undertaken to increase the per-share trading price, often to meet minimum bid price requirements for continued listing on exchanges like the Nasdaq Global Select Market. The reverse stock split will uniformly affect all stockholders, converting every ten existing shares into one new share, with cash paid in lieu of fractional shares.
Key Highlights
- Quince Therapeutics will effect a 1-for-10 reverse stock split.
- Stockholders approved the reverse stock split at the 2025 Annual Meeting on June 4, 2025.
- The Certificate of Amendment was filed on April 9, 2026, and will become effective at 11:59 pm Eastern Time on April 10, 2026.
- Shares of common stock will begin trading on a split-adjusted basis on the Nasdaq Global Select Market commencing upon market open on April 13, 2026.
- Every ten (10) shares of issued and outstanding common stock will be automatically combined and converted into one (1) issued and outstanding share.
- Stockholders who would otherwise receive fractional shares will receive cash in lieu of such fractional shares.